Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer

Huimin Zhang,Chunhong Qin,Changming An,Xiwang Zheng,Shuxin Wen,Wenjie Chen,Xianfang Liu,Zhenghua Lv,Pingchang Yang,Wei Xu,Wei Gao,Yongyan Wu

DOI: https://doi.org/10.1186/s12943-021-01431-6

IF: 37.3

2021-10-01

Molecular Cancer

Abstract:Abstract The 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna for the development of the Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease9 (CRISPR/Cas9) gene editing technology that provided new tools for precise gene editing. It is possible to target any genomic locus virtually using only a complex nuclease protein with short RNA as a site-specific endonuclease. Since cancer is caused by genomic changes in tumor cells, CRISPR/Cas9 can be used in the field of cancer research to edit genomes for exploration of the mechanisms of tumorigenesis and development. In recent years, the CRISPR/Cas9 system has been increasingly used in cancer research and treatment and remarkable results have been achieved. In this review, we introduced the mechanism and development of the CRISPR/Cas9-based gene editing system. Furthermore, we summarized current applications of this technique for basic research, diagnosis and therapy of cancer. Moreover, the potential applications of CRISPR/Cas9 in new emerging hotspots of oncology research were discussed, and the challenges and future directions were highlighted.

oncology,biochemistry & molecular biology